[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342648-105":59,"doc-detail-342648-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-pot1-founder-variant-associated-with-early-onset-recurrent-melanoma-and-various-solid-malignancies","A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies","","POT1 (Protection of Telomeres 1) is a shelterin complex component essential for telomere protection and length regulation. Germline POT1 variants have been linked to cancer predisposition, mainly melanoma and chronic lymphocytic leukemia. The study identifies POT1 p.(I78T) as a founder pathogenic variant in Ashkenazi Jews and characterizes its clinical profile using data from 2018–2023. Eleven carriers (ages 25–67) from ten families showed 30 primary malignancies, with recurrent melanoma common and multiple additional solid tumors, supported by frequency and shared haplotype findings.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-pot1-founder-variant-associated-with-early-onset-recurrent-melanoma-and-various-solid-malignancies/342648/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-pot1-founder-variant-associated-with-early-onset-recurrent-melanoma-and-various-solid-malignancies/342648.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the POT1 p.(I78T) variant in this study?","Question",{"text":113,"@type":114},"It is a germline POT1 variant (p.(I78T)) that the study identifies as a founder pathogenic variant with a characteristic clinical landscape in Ashkenazi Jews.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the cohort for the study collected?",{"text":118,"@type":114},"A directed database search identified individuals referred for genetic counselling from 2018 to 2023, followed by collection and analysis of demographic, clinical, genetic, and pathological data.",{"name":120,"@type":111,"acceptedAnswer":121},"What cancers were most frequently observed among carriers?",{"text":122,"@type":114},"Recurrent melanoma was the most prominent feature, occurring in most carriers within an early-to-mid age range, and additional tumors included desmoid tumors, papillary thyroid cancer, and breast cancer, along with other malignancies reported in the cohort.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},342648,1790555535,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nA POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies  \nAasem Abu Shtaya 1,2, Inbal Kedar 1, Lily Bazak 1, Lina Basel-Salmon 1,3,4,5, Sarit Farage Barhom 1, Michal Naftali 6, Marina Eskin-Schwartz 7,8, Ohad S. Birk 7,8, Shirley Polager-Modan 9, Nitzan Keidar 5, Gili Reznick Levi 10, Zohar Levi 3,11, Tamar Yablonski-Peretz 12,13, Ahmad Mahamid 14, Ori Segol 2, Reut Matar 1, Yifat Bareli 1, Noy Azoulay 1 and Yael Goldberg 1,3, *  \nCitation: Abu Shtaya, A.; Kedar, I.; Bazak, L.; Basel-Salmon, L.; Barhom, S.F.; Naftali, M.; Eskin-Schwartz, M.; Birk, O.S.; Polager-Modan, S.; Keidar, N.; et al. A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies. Genes 2024, 15, 355. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)genes15030355  \nAcademic Editor: Judith Fischer  \nReceived: 14 February 2024  \nRevised: 11 March 2024  \nAccepted: 11 March 2024  \nPublished: 13 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Recanati Genetics Institute, Rabin Medical Center—Beilinson Hospital, Petach Tikva 4941492, Israel;  \n[asemab@clalit.org.il](asemab@clalit.org.il) (A.A.S.); [inbalkd@clalit.org.il](inbalkd@clalit.org.il) (I.K.); [lilybazak@clalit.org.il](lilybazak@clalit.org.il) (L.B.);  \n[linab@clalit.org.il](linab@clalit.org.il) (L.B.-S.); [saritfa1@clalit.org.il](saritfa1@clalit.org.il) (S.F.B.); [matarre@clalit.org.il](matarre@clalit.org.il) (R.M.); [yifatba1@clalit.org.il](yifatba1@clalit.org.il) (Y.B.);  \n[noyaz@clalit.org.il](noyaz@clalit.org.il) (N.A.)  \n2 Unit of Gastroenterology, Lady Davis Carmel Medical Center, Haifa 3436212, Israel; [ori_segol@clalit.org.il](ori_segol@clalit.org.il)  \n3 Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; [zoharl@clalit.org.il](zoharl@clalit.org.il)  \n4 Felsenstein Medical Research Center, Petach Tikva 4920235, Israel  \n5 Pediatric Genetic Unit, Schneider Children’s Medical Center of Israel, Petch Tikva 4920235, Israel; [nitzankei@clalit.org.il](nitzankei@clalit.org.il)  \n6 Clalit Genomic Center, Petach Tikva 5252247, Israel; [michalnaf@clalit.org.il](michalnaf@clalit.org.il)  \n7 Genetics Institute, Soroka University Medical Center, Beer Sheva 8410101, Israel;  \n[blmarinaa@clalit.org.il](blmarinaa@clalit.org.il) (M.E.-S.); [obirk@bgu.ac.il](obirk@bgu.ac.il) (O.S.B.)  \n8 Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410101, Israel  \n9 Genetics Institute, Carmel Medical Center, Haifa 3436212, Israel; [shirlymd@clalit.org.il](shirlymd@clalit.org.il)  \n10 Genetics Institute, Rambam Health Care Campus, Haifa 3525408, Israel; [g_reznick@rmc.gov.il](g_reznick@rmc.gov.il)  \n11 Division of Gastroenterology, Rabin Medical Center—Beilinson Hospital, Petach Tikva 4941492, Israel  \n12 Oncology Institute, Hadassah Medical Center, Jerusalem 9112001, Israel; [tamary@hadassah.org.il](tamary@hadassah.org.il)  \n13 Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9190500, Israel  \n14 Department of Surgery B, Carmel Medical Center, Haifa 3436212, Israel; [ahmadma1@clalit.org.il](ahmadma1@clalit.org.il)  \n* [Correspondence: yaelgo43@gmail.com](Correspondence: yaelgo43@gmail.com); Tel.: +972-50-6-451900  \nAbstract: POT1 (Protection of Telomeres 1) is a key component of the six-membered shelterin complex that plays a critical role in telomere protection and length regulation. Germline variants in the POT1 gene have been implicated in predisposition to cancer, primarily to melanoma and chronic lymphocytic leukemia (CLL). We report the identification of POT1 p.(I78T), previously ranked with conflicting interpretatio","cbCaica8vSUAGKK1","https://ap.wps.com/l/cbCaica8vSUAGKK1","pdf",644350,"English","# Introduction\n## POT1 and telomere biology\n## Founder variant identification and study design\n## Clinical and genetic findings","[{\"question\":\"What is the POT1 p.(I78T) variant in this study?\",\"answer\":\"It is a germline POT1 variant (p.(I78T)) that the study identifies as a founder pathogenic variant with a characteristic clinical landscape in Ashkenazi Jews.\"},{\"question\":\"How was the cohort for the study collected?\",\"answer\":\"A directed database search identified individuals referred for genetic counselling from 2018 to 2023, followed by collection and analysis of demographic, clinical, genetic, and pathological data.\"},{\"question\":\"What cancers were most frequently observed among carriers?\",\"answer\":\"Recurrent melanoma was the most prominent feature, occurring in most carriers within an early-to-mid age range, and additional tumors included desmoid tumors, papillary thyroid cancer, and breast cancer, along with other malignancies reported in the cohort.\"}]","A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies | PDF",1790047541,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b89a989b6d07045c2bb4ee4ee10ac88.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a421fdbe696b9984ef2016c55d455c8.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc6de1b12bbb6aa5dabd16135f9472d2.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9851b1973f000664c237613047aa9d35.webp",980,1385]